Floatz logo

Shr-1701

Chemoradiotherapy

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Chemoradiotherapy cohort.

Asset / SponsorPhaseRating
Carboplatin
Shanghai Chest Hospital
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai Chest Hospital
Phase 3B
ETOPOSIDE
Shanghai Chest Hospital
Phase 3B
Capecitabine
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Phase 2/3B
Eloxatin
Kangbuk Samsung Hospital
Phase 2B

View all 11 →

Same molecule, other indications

Shr-1701 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →